Human neutralizing antibodies against hemolytic uremic syndrome
Human and humanized monoclonal antibodies which binds specifically to subunit A of Shiga like toxin II have been developed which are effective to prevent or ameliorate one or more symptoms of HUS in a human. Effective dosages for treatment or prevention range from approximately 0.1 to 5.0 mg of antibody/kg of patient weight. The examples demonstrate the preferred dosage ranges based on the pig model, and what is being tested in phase I clinical trials. Antibodies are preferably transfused over a period of two hours, although this will depend on the patient and the disease state at the time of treatment. Preferred dosages for treatment of humans are between 0.1 mg/kg-5.0 mg/kg of 5C120, or an equivalent dosage of another antibody to subunit A of STX2. In the most preferred embodiments, dosages of 0.1 mg/kg, 0.5 mg/kg, or 5.0 mg/kg of 5C12 (low dose, anticipated therapeutic dose based on animal data and high dose) are administered.
1. A method of treating a human to prevent or ameliorate one or more symptoms of hemolytic uremic syndrome (HUS) comprising administering human or humanized monoclonal antibodies or antibody fragments which only bind specifically to subunit A of the Shiga-like toxin II, in a dosage equal to or greater than 0.4 mg/kg to produce a mean serum concentration of at least 0.7 μg/ml effective to prevent or treat HUS.
2. The method of claim 1 wherein the human monoclonal antibodies which bind specifically to Shiga-like toxin II are neutralizing antibodies.
3. The method of claim 1 wherein the dosage is effective to prevent the human from developing HUS.
4. The method of claim 1 wherein the dosage is administered parenterally.
5. The method of claim 1 wherein the dosage is administered by injection.
6. The method of claim 1 wherein the dosage is administered as a single injection or infusion.
7. The method of claim 1 wherein the dosage is between 0.1 mg/kg-5.0 mg/kg of a neutralizing humanized monoclonal antibody selectively binding the alpha subunit of SLT-II and having a dissociation constant of 0.85 nM.
8. The method of claim 1 wherein a dose of 0.1 mg/kg, 0.5 mg/kg, or 5.0 mg/kg of a neutralizing humanized monoclonal antibody selectively binding the alpha subunit of SLT-II and having a dissociation constant of 0.85 nM is administered.
9. The method of claim 1 wherein the dosage is infused intravenously using an infusion pump over at least 2 hours.
10. The method of claim 1 , wherein the antibodies are produced by recombinant DNA methodology.
11. The method of claim 1 , wherein the antibodies are chimeric monoclonal antibodies.
12. The method of claim 1 wherein the antibodies are effective to prevent neurological signs of hemolytic uremic syndrome or lesions selected from the group consisting of cerebral hemorrhaging and convulsions.
13. The method of claim 1 , wherein the antibodies are effective to prolong survival.
14. The method of claim 1 , further comprising administering antibodies binding to the beta subunit of the Shiga-like toxin II.
15. The method of claim 1 in a dosage equivalent to 4 ml serum from an animal immunized with Shiga-like toxin II/kg body weight.
16. The method of claim 1 in a dosage producing a serum level of anti-Shiga toxin II antibodies of at least 0.5 micrograms/ml.
17. The method of claim 1 in a dosage of 3 mg human monoclonal antibody to Shiga-like toxin II administered to a newborn pig.